

Dated: July 21, 1999.

John C. Burckhardt,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 99-19084 Filed 7-26-99; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Workshop; The National Vaccine Program Office, National Vaccine Advisory Committee Announces the Following Workshop.

Name: Thimerosal in Vaccines.

Times and Dates: 9 a.m.-5 p.m., August 11, 1999, 9 a.m.-1 p.m., August 12, 1999.

Place: National Institutes of Health, Lister Hill Auditorium, Bethesda, Maryland.

Status: Open to the public, limited only by the space available.

Purpose: The agenda will include discussions on thimerosal in vaccines and its reduction and elimination from vaccines. Agenda items are subject to change as priorities dictate.

Notice: In the interest of security, the Department has instituted stringent procedures for entrance to the National Institutes of Health by non-government employees. Thus, persons without a government identification card should plan to arrive at the building each day

either between 8 and 8:30 a.m. or 12:30 and 1 p.m. so they can be escorted to the meeting. Entrance to the meeting at other times during the day cannot be assured.

Contact Person for More Information: Alicia Postema, National Vaccine Program Office, CDC, 1600 Clifton Road, NE, M/S A-11, Atlanta, Georgia 30333, telephone 404/639-4450.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and ATSDR.

Dated: July 20, 1999.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 99-19086 Filed 7-26-99; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[FDA 225-99-6000]

Memorandum of Understanding Between the Food and Drug Administration and the Federal Aviation Administration

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is providing notice of a memorandum of understanding (MOU) between FDA and the Federal Aviation Administration (FAA). The purpose of the MOU is to act in cooperation to reduce the incidents of aircraft illumination by laser projections into navigable airspace.

DATES: The agreement became effective November 25, 1998.

FOR FURTHER INFORMATION CONTACT: Casper E. Uldricks, Center for Devices and Radiological Health (HFZ-300), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-4692.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 20.108(c), which states that all written agreements and memoranda of understanding between FDA and others shall be published in the **Federal Register**, the agency is publishing notice of this MOU.

Dated: May 11, 1999.

William K. Hubbard,

Associate Commissioner for Policy Coordination.